Market Overview

Credit Suisse Believes Top Line Growth Matters More Than Margins For Stericycle

Share:
Related SRCL
Imperial Capital Initiates Stericycle With In-line
Benzinga's Top Initiations

In a report published Monday, Credit Suisse analyst Hamzah Mazari reiterated an Outperform rating and $140.00 price target on Stericycle (NASDAQ: SRCL).

In the report, Credit Suisse noted, “We believe that operating leverage given lack of infrastructure pre-PSC deal should lead to much higher than expected earnings power over the next 12-16 months. Recall that SRCL can run StrongPak through PSC infrastructure and cut out third party treatment/disposal costs (i.e. had 1 Part B facility vs 13 post deal) in addition to better optimizing route density/logistics. Our sense is that 12 cents of 2015 full year EPS accretion is low based on our channel checks and past environmental deals.”

Stericycle closed on Thursday at $119.23.

Latest Ratings for SRCL

DateFirmActionFromTo
Mar 2015Imperial CapitalInitiates Coverage onIn-line
Nov 2014Bank of AmericaMaintainsBuy
Sep 2014Goldman SachsDowngradesBuyNeutral

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

Posted-In: Credit Suisse Hamzah MazariAnalyst Color Reiteration Analyst Ratings

 

Related Articles (SRCL)

Around the Web, We're Loving...